34320 Bimekizumab efficacy in subgroups defined by prior systemic treatment in patients with moderate to severe plaque psoriasis - 12/09/22
Doi : 10.1016/j.jaad.2022.06.615
Le texte complet de cet article est disponible en PDF.
| Commercial Disclosure: These studies were funded by UCB Pharma. Medical writing support was provided by Costello Medical. |
© 2022
Publié par Elsevier Masson SAS.
Vol 87 - N° 3S
P. AB146 - septembre 2022 Retour au numéro
Article précédent
- 34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
- Bruce Strober, Carle Paul, Andrew Blauvelt, Diamant Thaçi, Boni Elewski, Katy White, Veerle Vanvoorden, Delphine Deherder, Fabienne Staelens, Kilian Eyerich
- 32937 Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: Responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension
- Joseph F. Merola, Akihiko Asahina, Christopher T. Ritchlin, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Jason Eells, Philip J. Mease
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?